Role of WNK kinases in regulating tubular salt and potassium transport and in the development of hypertension

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 2 57-2, 2005, Pages

  Gamba, Gerardo ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD LA SALLE   (Mexico)

Author keywords

Claudins; Distal tubule; Diuretics; Paracellular; Sodium chloride

Indexed keywords

BICARBONATE; BICARBONATE CHLORIDE ANTIPORTER; CHLORIDE ION; CLAUDIN; COTRANSPORTER; PHOSPHOTRANSFERASE; POTASSIUM CHANNEL; POTASSIUM ION; PROTEIN KINASE WNK1; PROTEIN KINASE WNK4; SODIUM CHLORIDE; SODIUM ION; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; CHLORIDE TRANSPORT; CHROMOSOME 12; CHROMOSOME 17; ELECTROLYTE DISTURBANCE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GORDON SYNDROME; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTRACELLULAR TRANSPORT; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; NEPHRON; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSEUDOHYPOALDOSTERONISM; REVIEW; SODIUM TRANSPORT;

EID: 12144272609     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00311.2004     Document Type: Review

References (54)

1. Achard JM, Warnock DG, Disse-Nicodeme S, Fiquet-Kempf B, Corvol P, Fournier A, and Jeunemaitre X. Familial hyperkalemic hypertension: phenotypic analysis in a large family with the WNK1 deletion mutation. Am J Med 114: 495-498, 2003.
2. Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, Carniti C, Perala NM, Pierotti MA, and Sariola H. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Mol Endocrinol 18: 1004-1017, 2004.
3. Arnold JE and Healy JK. Hyperkalemia, hypertension and systemic acidosis without renal failure associated with a tubular defect in potassium excretion. Am J Med 47: 461-472, 1969.
4. Beaudet AL, Scriver CR, Sly WS, and Valle D. Genetics, biochemistry, and molecular basis of variant human phenotypes. In: The Metabolic and Molecular Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, and Valle D. New York: Mc-Graw Hill, 2001, p. 3-45.
5. Bindels RJ. A molecular switch controlling renal sodium and potassium excretion. Nat Genet 35: 302-303, 2003.
6. --transporting epithelia. Proc Natl Acad Sci USA 100: 663-668, 2003.
7. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, and Simon DB. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 59: 710-717, 2001.
8. Delaloy C, Lu J, Houot AM, Disse-Nicodeme S, Gasc JM, Corvol P, and Jeunemaitre X. Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 23: 9208-9221, 2003.
9. Disse-Nicodeme S, Achard JM, Desitter I, Houot AM, Fournier A, Corvol P, and Jeunemaitre X. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet 67: 302-310, 2000.
10. Disse-Nicodeme S, Desitter I, Fiquet-Kempf B, Houot AM, Stern N, Delahousse M, Potier J, Ader JL, and Jeunemaitre X. Genetic heterogeneity of familial hyperkalaemic hypertension. J Hypertens 19: 1957-1964, 2001.
11. Dowd BF and Forbush B. PASK (proline-alanine-rich STE20-related kinase), a regulatory kinase of the Na-K-Cl cotransporter (NKCC1). J Biol Chem 278: 27347-27353, 2003.
12. Ganguly G. Aldosterone. In: Endocrine Regulation of Water and Electrolyte Balance, edited by Fray JCS and Goodman HM. New York: Oxford University Press, 2000, vol. III, p. 156-227.
13. Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 8: 93-102, 1986.
14. Gordon RD and Hodsman GP. The syndrome of hypertension and hyperkalaemia without renal failure: long term correction by thiazide diuretic. Scott Med J 31: 43-44, 1986.
15. Holden S, Cox J, and Raymond FL. Cloning, genomic organization, alternative splicing and expression analysis of the human gene WNK3 (PRKWNK3). Gene 335: 109-119, 2004.
16. Hoover RS, Monroy A, Gamba G, and Hebert SC. Phosphorylation and regulation of the rat thiazide-sensitive sodium chloride cotransporter by protein kinase C (PKC) (Abstract). J Am Soc Nephrol 10: 33A, 1999.
17. - flux in extrarenal epithelia. Proc Natl Acad Sci USA 101: 2064-2069, 2004.
18. - permeability is regulated by WNK4 kinase: insight into normal physiology and hypertension. Proc Natl Acad Sci USA 101: 14877-14882, 2004.
19. + secretion. Nat Genet 35: 372-376, 2003.
20. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CRW, Seckl JR, and Mullins JJ. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J Clin Invest 103: 683-689, 1999.
21. Lee BH, Min X, Heise CJ, Xu BE, Chen S, Shu H, Luby-Phelps K, Goldsmith EJ, and Cobb MH. WNK1 phosphorylates synaptotagmin 2 and modulates its membrane binding. Mol Cell 15: 741-751, 2004.
22. Majid DSA and Navar GL. Blockade of distal nephron sodium transport, attenuates pressure natriuresis in dogs. Hypertension 23: 1040-1045, 1994.
23. Mansfield TA, Simon DB, Farfel Z, Bia M, Tucci JR, Lebel M, Gutkin M, Vialettes B, Christofilis MA, Kauppinen-Makelin R, Mayan H, Risch N, and Lifton RP. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 16: 202-205, 1997.
24. Margolis BL and Lifschitz MD. The Spitzer-Weinstein syndrome: one form of type IV renal tubular acidosis and its response to hydrochlorothiazide. Am J Kidney Dis 7: 241-244, 1986.
25. Mayan H, Munter G, Shaharabany M, Mouallem M, Pauzner R, Holtzman EJ, and Farfel Z. Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. J Clin Endocrinol Metab 89: 4025-4030, 2004.
26. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, and Farfel Z. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 87: 3248-3254, 2002.
27. Min X, Lee BH, Cobb MH, and Goldsmith EJ. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 12: 1303-1311, 2004.
28. Moudgil A, Rodich G, Jordan SC, and Kamil ES. Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome. Pediatr Nephrol 15: 60-62, 2000.
29. Mune T, Rogerson FM, Nikkila H, Agarwal AK, and White PC. Human hypertension caused by mutations in the kidney isozyme of 11β- hydroxysteroid dehydrogenase. Nat Genet 10: 394-399, 1995.
30. O'Reilly M, Marshall E, Speirs HJ, and Brown RW. WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. J Am Soc Nephrol 14: 2447-2456, 2003.
31. Paver WK and Paulilne GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 35: 305-306, 1964.
32. - cotransporter in the nervous system: evidence for a scaffolding role of the kinase. J Biol Chem 278: 52848-52856, 2003.
33. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993.
34. Rader DJ, Cohen J, and Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111: 1795-1803, 2003.
35. Rossier BC. Negative regulators of sodium transport in the kidney: key factors in understanding salt-sensitive hypertension? J Clin Invest 111: 947-950, 2003.
36. Schambelan M, Sebastian A, and Rector FC Jr. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 19: 716-727, 1981.
37. Simon DB, Farfel Z, Ellison D, Bia M, Tucci J, and Lifton RP. Examination of the thiazide-sensitive Na-Cl cotransporter as a candidate gene in Gordon's syndrome (Abstract). J Am Soc Nephrol 6: 632, 1995.
38. Spitzer A, Edelmann CM Jr, Goldberg LD, and Henneman PH. Short stature, hyperkalemia and acidosis: a defect in renal transport of potassium. Kidney Int 3: 251-257, 1973.
39. Stokes GS, Gentle JL, Edwards KD, and Stewart JH. Syndrome of idiopathic hyperkalaemia and hypertension with decreased plasma renin activity: effects on plasma renin and aldosterone of reducing the serum potassium level. Med J Aust 2: 1050-1054, 1968.
40. Suastegui R, Martinez F, Plata C, and Gamba G. Regulation of the thiazide-sensitive Na-Cl cotransporter by activation of PKA and PKC (Abstract). J Am Soc Nephrol 7: 1291, 1996.
41. Verissimo F and Jordan P. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 20: 5562-5569, 2001.
42. Wang XY, Masilamani S, Nielsen J, Kwon TH, Brooks HL, Nielsen S, and Knepper MA. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 108: 215-222, 2001.
43. Wang Z, Yang CL, and Ellison DH. Comparison of WNK4 and WNK1 kinase and inhibiting activities. Biochem Biophys Res Commun 317: 939-944, 2004.
44. Weinstein SF, Allan DM, and Mendoza SA. Hyperkalemia, acidosis, and short stature associated with a defect in renal potassium excretion. J Pediatr 85: 355-358, 1974.
45. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, and Lifton RP. Human hypertension caused by mutations in WNK kinases. Science 293: 1107-1112, 2001.
46. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, and Lifton RP. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci USA 100: 680-684, 2003.
47. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, and New MI. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 2263-2266, 1995.
48. Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, and Cobb MH. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 275: 16795-16801, 2000.
49. Xu BE, Min X, Stippec S, Lee BH, Goldsmith EJ, and Cobb MH. Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J Biol Chem 277: 48456-48462, 2002.
50. Xu BE, Stippec S, Lenertz L, Lee BH, Zhang W, Lee YK, and Cobb MH. WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. J Biol Chem 279: 7826-7831, 2004.
51. Yamauchi K, Rai T, Kobayashi K, Sohara E, Suzuki T, Itoh T, Suda S, Hayama A, Sasaki S, and Uchida S. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci USA 101: 4690-4694, 2004.
52. Yang CL, Angell J, Mitchell R, and Ellison DH. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 111: 1039-1045, 2003.
53. Yang CL and Ellison DH. WNK1 interacts physically with WNK4 (Abstract). J Am Soc Nephrol 14: 77A, 2003.
54. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van SI, Vogel P, Walke W, Xu N, Zhu Q, Person C, and Sands AT. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100: 14109-14114, 2003.